CSCs are thought to
drive tumor recurrence, progression, metastasis and drug resistance.
Not exact matches
ON THE ROAD Breast cancer cells may break away from the main
tumor in clumps, already bearing most of the mutations that will
drive cancer
recurrence, a study suggests.
Tumor recurrence was faster and more likely among African American patients, particularly for basal subtype
tumors or those
driven by the TP53 mutation.
This variation may
drive drug resistance and
tumor recurrence.